Cutaneous reactions occurred in most participants in a Netherlands-based multiple sclerosis therapy study, lowering dermatologic-specific quality-of-life scores.
This article was originally published on the Specialty Pharmacy Times website.
Although the results of a recent study suggest that severe cutaneous reactions to disease- modifying multiple sclerosis (MS) therapy are relatively common, the reactions only somewhat limit patients’ quality of life.
The study, published in the October 16, 2013, edition of BMC Neurology, analyzed 229 participants with relapse-remitting MS or clinically isolated syndrome suggestive of MS, who received treatment with their first disease-modifying therapy for at least 2 years, and assessed both generic quality-of-life and dermatologic quality-of-life scores. Treating neurologists assessed skin reactions during study visits and recorded reactions reported by participants. In addition, digital photographs of all participants’ injection sites were taken and then assessed by dermatologists.
More than half—68%—of patients had at least 1 cutaneous adverse event, according to the dermatologists’ assessments. The rate was comparable to that of the participants’ self-reporting, although it was consistently lower than the prevalence of reactions reported by neurologists, the authors noted.
Disease-modifying therapies included in the study were subcutaneous glatiramer acetate, subcutaneous interferon beta-1a, intramuscular interferon beta-1a, and subcutaneous interferon beta-1b.
Nineteen percent of participants received glatiramer acetate, 26% of participants received interferon beta-1b, 29% received subcutaneous interferon beta-1a, and 26% received intramuscular interferon beta-1a.
Within the treatment arms, 24 of the 59 participants receiving intramuscular interferon beta-1a experienced cutaneous adverse events, which was the lowest frequency in all of the treatment arms. The frequency of cutaneous events was comparable within the other treatment arms, with 75% of participants receiving either glatiramer acetate or subcutaneous interferon beta-1b experiencing symptoms, and 82% of participants in the subcutaneous interferon beta-1a group experiencing symptoms.
Erythema and lipoatrophy were the most common reactions, and were observed in 68% and 20% of participants, respectively, whereas ecchymosis was observed in 9% of participants, postinflammatory hyperpigmentation was observed in 7% of participants, eczema-like reactions were observed in 6% of participants, healed scars were observed in 3% of participants, and urticaria was observed in 2% of participants. Skin necrosis, varicose veins, and subcutaneous swelling were observed in just 0.4% of participants each.
Although redness or rash was the most common skin reaction among all treatment arms, participants receiving intramuscular interferon beta-1a had the lowest proportion of that reaction compared with the other 3 therapies. Lipoatrophy, the second most common skin reaction, was seen mostly in participants receiving glatiramer acetate, whereas participants receiving subcutaneous interferon beta-1b and glatiramer acetate were more likely to experience postinflammatory hyperpigmentation. Eczema also had a higher prevalence in participants receiving subcutaneous interferon beta-1b than in the other treatment arms. Cutaneous ulcers had a higher prevalence in participants receiving glatiramer acetate.
Click here to access the full-text version of this article on the Specialty Pharmacy Times website.